

Tai Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2387252/publications.pdf>

Version: 2024-02-01

21
papers

825
citations

623734

14
h-index

752698

20
g-index

22
all docs

22
docs citations

22
times ranked

1087
citing authors

#	ARTICLE	IF	CITATIONS
1	Disease-specific interactome alterations via epichaperomics: the case for Alzheimer's disease. <i>FEBS Journal</i> , 2022, 289, 2047-2066.	4.7	12
2	The penalty of stress - Epichaperomes negatively reshaping the brain in neurodegenerative disorders. <i>Journal of Neurochemistry</i> , 2021, 159, 958-979.	3.9	14
3	Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer. <i>Communications Biology</i> , 2021, 4, 1333.	4.4	11
4	A Chemical Biology Approach to the Chaperome in Cancer - HSP90 and Beyond. <i>Cold Spring Harbor Perspectives in Biology</i> , 2020, 12, a034116.	5.5	32
5	Gold/alpha-lactalbumin nanoprobe for the imaging and treatment of breast cancer. <i>Nature Biomedical Engineering</i> , 2020, 4, 686-703.	22.5	65
6	Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. <i>Cell Reports</i> , 2020, 31, 107840.	6.4	32
7	The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction. <i>Nature Communications</i> , 2020, 11, 319.	12.8	46
8	Chaperome Networks - Redundancy and Implications for Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1243, 87-99.	1.6	17
9	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. <i>Cancer Cell</i> , 2019, 36, 559-573.e7.	16.8	40
10	The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and activity. <i>PLoS ONE</i> , 2019, 14, e0208287.	2.5	23
11	Chaperome heterogeneity and its implications for cancer study and treatment. <i>Journal of Biological Chemistry</i> , 2019, 294, 2162-2179.	3.4	37
12	Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma. <i>Blood</i> , 2019, 134, 4399-4399.	1.4	0
13	HSP90-incorporating chaperome networks as biosensor for disease-related pathways in patient-specific midbrain dopamine neurons. <i>Nature Communications</i> , 2018, 9, 4345.	12.8	40
14	Adapting to stress - chaperome networks in cancer. <i>Nature Reviews Cancer</i> , 2018, 18, 562-575.	28.4	105
15	Proteomic interrogation of HSP90 and insights for medical research. <i>Expert Review of Proteomics</i> , 2017, 14, 1105-1117.	3.0	18
16	Long-Lasting and Fast-Acting in Vivo Efficacious Antiplasmodial Azepanylcarbazole Amino Alcohol. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 1304-1308.	2.8	12
17	The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , 2016, 538, 397-401.	27.8	233
18	Inhibition of <i>Plasmodium falciparum</i> Hsp90 Contributes to the Antimalarial Activities of Aminoalcohol-carbazoles. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6344-6352.	6.4	34

#	ARTICLE	IF	CITATIONS
19	Stressing Out Hsp90 in Neurotoxic Proteinopathies. <i>Current Topics in Medicinal Chemistry</i> , 2016, 16, 2829-2838.	2.1	14
20	Differences in Conformational Dynamics between <i>Plasmodium falciparum</i> and Human Hsp90 Orthologues Enable the Structure-Based Discovery of Pathogen-Selective Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2524-2535.	6.4	38
21	Overview of Molecular Chaperones in Health and Disease. <i>RSC Drug Discovery Series</i> , 2013, , 1-36.	0.3	2